Quality metrics for stem cell-derived cardiac myocytes

Area of Science:

• Cardiovascular Research
• Stem Cell Biology
• Biomedical Engineering

Background:

• Industrial-scale production of stem cell-derived cardiac myocytes is now feasible for in vitro research.
• Current FDA quality assurance focuses on safety, lacking standardized guidelines for myocyte functionality assessment.
• Uncertainty exists regarding the functional similarity and recapitulation of native myocyte characteristics among commercial cell lines.

Purpose of the Study:

• To develop and demonstrate a multiparametric quality assessment rubric for stem cell-derived cardiac myocytes.
• To establish standardized guidelines for evaluating myocyte functionality.
• To compare the performance of commercial stem cell-derived myocytes against native ventricular myocyte phenotypes.

Main Methods:

• A multiparametric quality assessment rubric was proposed, integrating genetic, structural, electrophysiological, and contractile measurements.
• Measurements were compared against established values representative of the native ventricular myocyte phenotype.
• Commercially available murine embryonic stem cell- and induced pluripotent stem cell-derived myocytes were tested using coupled in vitro assays.

Main Results:

• The study demonstrated the application of the proposed quality assessment rubric.
• Performance metrics of commercial stem cell-derived myocytes were evaluated against a neonatal mouse ventricular myocyte target phenotype.
• The rubric facilitated a comparative analysis of myocyte functionality.

Conclusions:

• A novel multiparametric rubric provides a framework for assessing stem cell-derived cardiac myocyte functionality.
• Standardized functional assessment is crucial for ensuring the reliability of in vitro research using these cells.
• This approach aids in determining if commercial cell lines accurately model native cardiac myocytes.